2013-03-25 13:01:57 -
Biofrontera AG /
Maschmeyer increases share holding in Biofrontera AG
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, 25 March 2013 - Dr. Carsten Maschmeyer participated in a capital
increase of Biofrontera AG last year, purchasing 12.5% of the share capital of
Biofrontera. Today he has informed Biofrontera AG that his investment companies
have purchased additional shares at the stock market, up to a share holding of
15.1% (2,437,618 shares). We refer to our obligatory press release according to
§26 of the German Securities Trading Act.
Dr. Maschmeyer has furthermore informed us that he is even more convinced of an
excellent development of Biofrontera's business than last year, and he intends
to keep the shares long-term, both those purchased
last year and those now,
beyond a holding period ending in April 2013 he had agreed to last year. He
intends to increase his share holding even further since he is convinced of a
The board of Biofrontera AG specifies that these assumptions and intents are
those of Dr. Maschmeyer, and the company is not allowed to comment them. His
actions confirm that Dr. Maschmeyer is a reliable and long-term investor for
About Biofrontera AG
Biofrontera aims at attending and treating the skin, recognizing the aesthetic
needs of a person's visual reflection.
Biofrontera is listed in the regulated market of the Frankfurt stock exchange
under the symbol B8F and the ISIN DE0006046113.
For further information:
Prof. Dr. Hermann Lübbert
+49 (0)214 876 32 0
+49 (0)214 876 32 90
Hemmelrather Weg 201
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE